Analysts Set Rezolute, Inc. (NASDAQ:RZLT) Target Price at $26.43

Shares of Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) have received a consensus rating of "Buy" from the seven analysts that are covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $26.43.

A number of research firms have recently commented on RZLT. Craig Hallum upgraded shares of Rezolute to a "strong-buy" rating in a report on Tuesday, February 4th. JMP Securities increased their target price on Rezolute from $8.00 to $9.00 and gave the company a "market outperform" rating in a research note on Thursday, February 13th. HC Wainwright restated a "buy" rating and issued a $14.00 price target on shares of Rezolute in a research note on Monday. Finally, Guggenheim reaffirmed a "buy" rating on shares of Rezolute in a report on Monday, February 10th.

Insider Activity at Rezolute

In other Rezolute news, CEO Nevan C. Elam purchased 12,302 shares of Rezolute stock in a transaction dated Thursday, March 27th. The stock was purchased at an average price of $2.85 per share, with a total value of $35,060.70. Following the transaction, the chief executive officer now directly owns 224,119 shares of the company's stock, valued at $638,739.15. This trade represents a 5.81 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Wladimir Hogenhuis acquired 10,000 shares of the stock in a transaction dated Tuesday, February 18th. The stock was acquired at an average price of $4.70 per share, for a total transaction of $47,000.00. Following the purchase, the director now directly owns 77,267 shares in the company, valued at approximately $363,154.90. This trade represents a 14.87 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 39,060 shares of company stock worth $130,694. 18.39% of the stock is owned by insiders.

Institutional Investors Weigh In On Rezolute

A number of hedge funds have recently modified their holdings of RZLT. Jeppson Wealth Management LLC purchased a new position in Rezolute during the first quarter valued at $35,000. Alpine Global Management LLC purchased a new position in shares of Rezolute during the 4th quarter valued at about $54,000. Woodline Partners LP lifted its position in shares of Rezolute by 2,817.1% during the 4th quarter. Woodline Partners LP now owns 1,089,345 shares of the company's stock valued at $5,338,000 after buying an additional 1,052,002 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of Rezolute by 48.5% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 19,799 shares of the company's stock valued at $97,000 after acquiring an additional 6,470 shares during the period. Finally, Point72 Europe London LLP purchased a new stake in Rezolute in the 4th quarter worth approximately $720,000. Institutional investors own 82.97% of the company's stock.

Rezolute Trading Down 2.3 %

NASDAQ:RZLT traded down $0.09 during trading hours on Friday, reaching $3.76. 842,907 shares of the company traded hands, compared to its average volume of 593,271. The business's 50-day moving average price is $3.36 and its two-hundred day moving average price is $4.44. Rezolute has a 1 year low of $2.22 and a 1 year high of $6.19. The stock has a market capitalization of $227.61 million, a P/E ratio of -3.08 and a beta of 0.97.

Rezolute (NASDAQ:RZLT - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.11. As a group, equities analysts anticipate that Rezolute will post -0.93 EPS for the current year.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.